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Tumor metastasis is one of the most serious challenges for human cancers as the majority of deaths caused by cancer are asso-
ciated with metastasis, rather than the primary tumor. Recent studies have demonstrated that tumor cell plasticity plays a criti-
cal role in tumor metastasis by giving rise to various cell types which is necessary for tumor to invade adjacent tissues and 
form distant metastasis. These include differentiation of cancer stem cells (CSCs), or epithelial-mesenchymal transition (EMT) 
and its reverse process, mesenchymal-epithelial transition (MET). A growing body of evidence has demonstrated that the bi-
ology of tumor cell plasticity is tightly linked to functions of non-coding RNAs (ncRNAs), especially microRNAs (miRNAs) 
and long non-coding RNAs (lncRNAs). Therefore, understanding the mechanisms how non-coding RNAs regulate tumor cell 
plasticity is essential for discovery of new diagnostic markers and therapeutic targets to overcome metastasis. 
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Tumor cell plasticity describes the ability of tumor cells to 
transform into other cell types. This process generates cells 
with new phenotypes ensuring their proliferation and me-
tastasis. Cancer stem cells (CSCs) are cancer cells that pos-
sess characteristics associated with normal stem cells, espe-
cially the ability to give rise to all cell types found in a par-
ticular tumor [1,2]. 
Epithelial-mesenchymal transition (EMT) is the process 
by which epithelial cells lose epithelial characteristics and 
gain mesenchymal characteristics. During EMT, epithelial 
cells lose cell-cell junctions, thus facilitating cell individu-
alization. In addition, the epithelial apical-basal polarity is 
lost, and a complete reorganization of the actin cytoskeleton 
enhances cell locomotion along rear-to-front polarity. EMT 
also enables cells to acquire invasive properties, thus de-
grading extracellular matrix and re-synthesizing extracellu-
lar matrix proteins [3,4]. Transcription factors Snail (Snail/ 
Slug), ZEB (ZEB1/ZEB2), and Twist1 act to repress E- 
cadherin expression, and induce mesenchymal gene expres-
sion, such as vimentin and fibronectin in this transition [5]. 
In carcinomas, cancer cells can undergo EMT to escape the 
primary tumor, invade surrounding tissues, and eventually 
colonize remote sites via blood or lymphatic routes to gen-
erate metastases. Metastatic cells can then revert through 
mesenchymal-epithelial transition (MET) to re-acquire epi-
thelial characteristics similar to cells in the primary tumor. 
Therefore, development of specific therapies targeted at 
CSCs and EMT holds hope for improvement of survival and 
quality of life of cancer patients, especially for sufferers of 
metastatic disease. The molecular and cellular mechanisms 
underlying CSCs and EMT are complex. The discovery that 
non-coding RNAs (ncRNAs) are powerful regulators of 
CSCs and EMT has added an important new layer to our 
understanding of tumor cell plasticity and the regulation of 
these processes in cancer. 
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1  Classification of ncRNAs 
Non-coding RNAs (ncRNAs) are RNA molecules that do 
not function by encoding for proteins. They are loosely 
grouped into two major classes based on their size: small 
ncRNAs less than 200 nt, and long ncRNAs (lncRNAs) 
longer than 200 nucleotides (nt) [6,7]. Small ncRNAs are 
represented by a broad range of known and newly discov-
ered RNA species [8,9]. These include well-characterized 
housekeeping ncRNAs such as tRNA and rRNA which are 
essential for fundamental cellular functions, splicing RNAs 
(snRNAs) that regulates mRNA splicing, and a variety of 
recently-observed RNAs regulating transcription, such as 
tiny transcription-initiation RNAs, promoter-associated 
short RNAs and termini-associated short RNAs. However, 
the most extensively studied small RNAs in cancer are mi-
croRNAs (miRNAs) [6,7]. 
miRNAs are small double-strand RNAs at ~22 nt long. 
They regulate protein expression at post-transcriptional lev-
el by binding to the 3′UTRs of target mRNAs, which leads 
to translation repression or target mRNA cleavage [10,11]. 
miRNAs are grouped into families based on similarity of 
seed sequences. Members of a family are expected to have 
many overlapping targets. Therefore, individual miRNAs 
often target multiple mRNAs within a common pathway, 
increasing the robustness of their effects on cellular pro-
cesses such as EMT, while single mRNAs can be regulated 
by multiple miRNAs [12]. 
In contrast to miRNAs, lncRNAs are mRNA-like tran-
scripts ranging in length from 200 nt to ~100 kilobases (kb) 
lacking significant open reading frames. Many identified 
lncRNAs are transcribed by RNA polymerase II (RNA  
pol II) and are polyadenylated [13,14]. Transcription of 
lncRNAs occurs from an independent gene promoter and is 
not coupled to the transcription of a nearby or associated 
parental gene, as with promoter/termini associated RNAs 
[6]. Although only a minority have been characterized in 
detail, lncRNAs participate in diverse biological processes 
through distinct mechanisms. Generally, lncRNAs have 
been implicated in chromosome dosage-compensation, im-
printing, epigenetic regulation, cell cycle control, nuclear 
and cytoplasmic trafficking, transcription, translation, 
splicing, cell differentiation, and others [1519]. 
2  miRNA regulation of CSCs and EMT 
Breast CSCs (BCSCs) were the first CSCs in solid tumors 
to be reported and are among the best characterized CSCs 
[20]. BCSCs can be enriched by consecutively passaging 
breast cancer cell SKBR3 in mice treated with chemothera-
py [21]. These xenografts contain a high percentage of 
stem-like CD44+/CD24 cells. Importantly, the BCSC-  
enriched cells expressed much lower levels of let-7 as well 
as a number of other miRNAs, including miR-16, miR-107, 
miR-128, and miR-20b, than the parental cells. let-7 regu-
lated self-renewal and differentiation of BCSCs by targeting 
H-RAS and HMGA2, respectively. Overexpression of let-7a 
inhibited mammosphere formation, tumor formation, and 
metastasis in NOD/SCID mice and reduced the proportion 
of undifferentiated cells in vitro. Subsequently, miR-30 was 
also found to be markedly reduced in BCSCs and to nega-
tively modulate the stemness of BCSCs. Overexpression of 
miR-30 in BCSCs not only diminished their self-renewal 
ability but also reduced anoikis resistance and increased 
apoptosis by targeting UBC9 and integrin 3. A more com-
plete inhibition of self-renewal in BCSCs was observed 
when both let-7 and miR-30 were introduced at the same 
time, compared with transfecting either miRNA alone. The 
synergistic inhibitory effects of let-7 and miR-30 suggest 
that multiple miRNAs may distinctively and concertedly 
regulate CSC properties [22].  
Furthermore, miR-17-19b is up-regulated in leukemia 
stem cells, consistent with reduced differentiation and in-
creased proliferation, in part by modulating the expression 
of p21 [23]. miR-34a was found to be down-regulated in 
human glioblastomas. Transfection of miR-34a into glio-
blastoma multiforme (GBM) CSCs caused cell-cycle arrest 
or apoptosis and also inhibited xenograft growth, mediated 
by down-regulation of multiple oncogenic targets, including 
c-MET, Notch-1/2, and CDK6 [24]. The miR-181 is im-
portant for the maintenance of hepatic cancer stem cells by 
down-regulating two hepatic transcriptional regulators 
promoting differentiation (CDX2 and GATA6) and an in-
hibitor of Wnt/-catenin signaling (NLK) [25]. 
Several miRNAs directly target families of EMT tran-
scription factors. For example, the transcription factors 
ZEB1 and ZEB2 have been confirmed as targets of 
miR-200 family [26,27]. Conversely, ZEB1 represses the 
transcription of miR-200 genes by binding to their promoter 
region, thereby forming a double-negative feedback loop 
[28]. A striking negative correlation was found between 
ZEB and miR-200 expression in many human cancer cell 
lines. miR-205 was also reported to inhibit ZEB1 and ZEB2 
expression [26]. Snail is targeted by miR-29b and miR-30a 
[29,30]. Accordingly, enhanced expression of miR-29b in 
metastatic prostate cancer cells reverses EMT and inhibits 
the invasive phenotype. Furthermore, miR-1 and miR-200b 
both directly target Slug in prostate adenocarcinoma cells 
[31]. In this system, TGF--induced EMT results in expres-
sion of Slug, which in turn transcriptionally represses the 
expression of both miR-1 and miR-200b, forming a double 
negative feedback loop. miR-200b and miR-15b were 
down-regulated in cisplatin-resistant tongue squamous cell 
carcinoma (TSCC) cells, which show the acquisition of 
EMT phenotype. Re-expression of miR-200b and miR-15b 
induced MET with up-regulated E-cadherin expression, 
down-regulated vimentin and fibronectin expressions, and 
inhibited invasion and migration in cisplatin-resistant cells 
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by targeting BMI1. In vivo, miR-200b or miR-15b sup-
pressed metastasis of TSCC xenografts established by cis-
platin-resistant cells [32].  
Mani et al. [33] first firmly connected EMT and CSCs by 
inducing HMLE cells to undergo EMT by Snail or Twist 
and revealed that the EMT markers are highly expressed in 
human mammary CSCs that were CD44high/CD24low and 
were able to form mammospheres. Subsequently, the con-
nection of EMT and CSCs was demonstrated in many other 
human cancers. miR-21 acts as oncogenic miRNA, and its 
expression promotes EMT and CSC characteristics in breast 
cancer cells, notably through inhibition of PTEN expression 
[34,35]. Expression of the miR-106b-25 cluster, which acts 
downstream of the transcription factor Six1, induces EMT 
and tumor-initiating characteristics in human breast cancer 
cells, through direct repression of Smad7, thus increasing 
TGF- signaling [36]. Linking EMT and CSCs to specific 
miRNAs will enable us to better understand how metastatic 
cancer arisen and targeting these regulatory miRNAs may 
provide new ways to overcome cancer. 
3  lncRNAs in cancer 
According to recent results from ENCODE project, 62% of 
human genome is coding for transcripts longer than 200 nt, 
yet only 5.5% of them is represented by coding exons. It is 
estimated that the total number of lncRNAs is between 
10000 and 200000 [37]. However, only very few examples 
of lncRNAs have been functionally characterized [15,38]. 
Recent studies show that lncRNAs are exquisitely regulated 
during development and in response to diverse signaling 
cues, and can be misexpressed in solid tumors and leukemi-
as [39], suggesting that lncRNAs constitute an important 
component of tumor biology. One of the first lncRNAs de-
scribed to have fundamental roles in cancer was the HOX 
antisense intergenic RNA (HOTAIR), encoded by a 2.2 kb 
gene located in the mammalian HOXC locus on chromo-
some 12q13.13 [40]. This lncRNA was found to be highly 
up-regulated in both primary and metastatic breast tumors. 
High levels of HOTAIR expression were correlated with 
both metastasis and poor survival rate [41].  
The MALAT1 gene, or metastasis-associated lung ade-
nocarcinoma transcript 1, was first associated with high 
metastatic potential and poor patient prognosis during a 
comparative screen of non-small cell lung cancer patients 
with and without metastatic tumors [42]. Recently, Ying et al. 
[43] found that MALAT-1 levels were up-regulated in 
bladder cancer tissues compared with adjacent normal tis-
sues, and siRNA-mediated MALAT-1 silencing resulted in 
a decrease of ZEB1, ZEB2 and Slug levels, and an increase 
of E-cadherin levels. MALAT-1 promoted EMT by activat-
ing Wnt signaling in vitro. These data suggest a potential 
application of MALAT-1 in cancer therapy. 
Several lncRNAs are implicated in the regulation of p53 
tumor suppressor signaling. MEG3, a maternally-expressed 
imprinted lncRNA on Chr14q32, has been shown to activate 
p53 and facilitate p53 signaling, including enhancing p53 
binding to target gene promoters [44]. MEG3 overexpres-
sion suppresses cell proliferation in meningioma [45] and 
hepatocellular carcinoma cell lines [46]. A recently de-
scribed murine lncRNA located near the p21 gene, termed 
linc-p21, has also emerged as a promising p53-pathway 
gene. In murine lung, sarcoma, and lymphoma tumors, 
linc-p21 expression is induced upon activation of p53 sig-
naling and represses p53 target genes through a physical 
interaction with hnRNP-K, a protein that binds the promot-
ers of genes involved in p53 signaling. linc-p21 is further 
required for proper apoptotic induction [47]. These two 
lncRNAs may be a putative tumor suppressor.  
Recent research has shed light on the possibilities that 
lncRNAs could regulate crucial signal pathways in tumor 
cell biology. lncRNA low expression in tumor (lncRNA- 
LET) is down-regulated in hepatocellular carcinomas and 
other types of cancers. It is down-regulated by hypox-
ia-induced histone deacetylase 3, and down-regulation of 
lncRNA-LET enables stabilization of nuclear factor 90 pro-
tein, which leads to hypoxia-induced cell invasion [48]. 
Another study shows that two lncRNAs, PRNCR1 and 
PCGEM1, bind to androgen receptor and are required for 
ligand-dependent activation of androgen receptor pathway. 
Moreover, their pathological up-regulation can trigger lig-
and-independent activation of androgen receptor pathway 
and may facilitate castration resistance in prostatic tumors 
[49]. These examples have raised the possibility that 
lncRNAs may play significant roles in tumor cell plasticity 
by being involved in regulation of critical signal pathways. 
4  Concluding remarks and future perspectives 
Malignant tumors are heterogeneous in their cellular com-
ponents. Tumor cells vary in their tumorigenicity, ability to 
metastasis, and resistance to therapies. This nature of tumor 
cells is governed by both genetic heterogeneity and cellular 
plasticity. Growing evidence suggests that cellular plasticity 
is tightly linked to tumor progression, metastasis, resistance 
to therapies, and relapse. Recent studies show non-coding 
RNAs played a critical role in regulating tumor cell plastic-
ity. These mainly include miRNAs and lncRNAs, as they 
exert their functions by regulating gene expression which is 
essential mechanism of cell plasticity (Table 1). Future ex-
plorations of expressions and functions of these expres-
sion-regulating molecules in human cancer may lead to 
discoveries of new markers for diagnosis or developments 
of targeted therapeutics. 
Challenges of analyzing functions of cancer related 
ncRNAs mainly involve specifically modulation of their 
expressions. While genetic knock-outs of certain pro-
tein-coding genes are often achieved by introducing a stop 
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Table 1  ncRNAs regulating tumor cell plasticity 
ncRNA Summary Reference 
miRNA   
let-7 
Down-regulated in breast cancer stem cells, regulate breast cancer stem cell differentiation by tar-
geting H-RAS and HMGA2 
[21] 
miR-30 
Down-regulated in breast cancer stem cells, regulate self-renewal and anoikis resistance by target-
ing UBC9 and integrin β3 [22,30] 
miR-17/miR-19b Up-regulated in leukemia stem cells, regulate proliferation by targeting p21 [23] 
miR-34 
Down-regulated in glioblastomas, regulate cell-cycle or apoptosis by targeting c-MET, Notch-1/2, 
and CDK6 
[24] 
miR-181 Up-regulated in hepatic cancer stem cells, maintain stemness by targeting CDX2, GATA6 and NLK [25] 
miR-200 family Down-regulated in EMT, regulate EMT by targeting ZEB1/2 [2628] 
miR-205 Regulate ZEB1/2 and repress EMT [26] 
miR-29b Reverse EMT and inhibit invasion in prostate cancer cells [29] 
miR-1 Target Slug to inhibit EMT in prostate adenocarcinoma cells [31] 
miR-15b 
Down-regulated in chemotherapy induced EMT, synergistically regulate chemoresistance and inva-
sion with miR-200b by targeting BMI1 
[32] 
miR-21 Target PTEN to promote EMT and cancer stem cell characteristics [34,35] 
miR-106b-25 Target SMAD7 to induce EMT in TGF-β treated breast cancer cells [36] 
lncRNA   
HOTAIR 
Up-regulated in metastatic breast tumors, indicate poor prognosis, enhance metastasis by modulat-
ing chromatin state 
[40,41] 
MALAT1 Up-regulated in metastatic lung adenocarcinomas, promote EMT by enhancing ZEB1/2 expression [42,43] 
MEG3 Involved in p53 signaling, suppress cell proliferation [4446] 
linc-p21 Activated by p53 and mediate p53 induced apoptosis [47] 
lncRNA-LET Down-regulated by hypoxia and mediate hypoxia-induced invasion [48] 
PRNCR1/PCGEM1 Activate androgen-receptor pathway and facilitate castration-resistance in prostate cancer [49] 
 
codon in the translated sequences, this strategy is not appli-
cable for long non-coding RNA transcripts as the transcripts 
themselves are the functional units. Other knock-out strate-
gies such as disruption of core promoters of ncRNA genes 
are complicated by the nature that ncRNAs genes are often 
associated with protein-coding genes. Furthermore, silenc-
ing efficiencies of lncRNAs by siRNAs are often lower than 
proteins, because lncRNAs often form stable secondary 
structures that preclude binding of siRNAs to the target se-
quence. These challenges need to be overcome by develop-
ing new strategies to modulate ncRNA expression or build-
ing new models for functional studies in future. 
This work was supported by the National Basic Research Program of China 
(2010CB912800, 2011CB504203), National Natural Science Foundation 
of China (81230060, 81261140373), National Science and Technology 
Major Special Project on New Drug Innovation of China (2011ZX09102- 
010-02), Science Foundation of Guangdong Province (S2012030006287), 
and Key Laboratory of Malignant Tumor Gene Regulation and Target 
Therapy of Guangdong Higher Education Institutes, Sun Yat-sen Universi-
ty (KLB09001). 
1 Scaffidi P, Misteli T. In vitro generation of human cells with cancer 
stem cell properties. Nat Cell Biol, 2011, 13: 1051–1061 
2 Gupta P B, Chaffer C L, Weinberg R A. Cancer stem cells: Mirage or 
reality? Nat Med, 2009, 15: 1010–1012 
3 Thiery J P, Acloque H, Huang R Y, et al. Epithelial-mesenchymal 
transitions in development and disease. Cell, 2009, 139: 871–890 
4 Thiery J P, Sleeman J P. Complex networks orchestrate epitheli-
al-mesenchymal transitions. Nat Rev Mol Cell Biol, 2006,7: 131–142 
5 Peinado H, Olmeda D, Cano A. Snail, Zeb and bHLH factors in tu-
mour progression: An alliance against the epithelial phenotype? Nat 
Rev Cancer, 2007, 7: 415–428 
6 Gibb E A, Brown C J, Lam W L. The functional role of long 
non-coding RNA in human carcinomas. Mol Cancer, 2011, 10: 38 
7 Brosnan C A, Voinnet O. The long and the short of non-coding 
RNAs. Curr Opin Cell Biol, 2009, 21: 416–425 
8 Okamura K, Chung W J, Ruby J G, et al. The Drosophila hairpin 
RNA pathway generates endogenous short interfering RNAs. Nature, 
2008, 453: 803–806 
9 Kawaji H, Hayashizaki Y. Exploration of small RNAs. PLoS Genet, 
2008, 4: e22 
10 Bartel D P. microRNAs: Target recognition and regulatory functions. 
Cell, 2009, 136: 215–233 
11 Carthew R W, Sontheimer E J. Origins and mechanisms of miRNAs 
and siRNAs. Cell, 2009, 136: 642–655 
12 Subramanyam D, Blelloch R. From microRNAs to targets: Pathway 
discovery in cell fate transitions. Curr Opin Genet Dev, 2011, 21: 
498–503 
13 Cheng J, Kapranov P, Drenkow J, et al. Transcriptional maps of 10 
human chromosomes at 5-nucleotide resolution. Science, 2005, 308: 
1149–1154 
14 Wu Q, Kim Y C, Lu J, et al. Poly A transcripts expressed in HeLa 
cells. PLoS ONE, 2008, 3: e2803 
15 Guttman M, Amit I, Garber M, et al. Chromatin signature reveals 
over a thousand highly conserved large non-coding RNAs in mam-
mals. Nature, 2009, 458: 223–227 
16 Mattick J S. The genetic signatures of noncoding RNAs. PLoS Genet, 
2009, 5: e1000459 
17 Mattick J S, Makunin I V. Non-coding RNA. Hum Mol Genet, 2006, 
15(Suppl 1): R17–R29 
18 Qureshi I A, Mattick J S, Mehler M F. Long non-coding RNAs in 
nervous system function and disease. Brain Res, 2010, 1338: 20–35 
19 Wilusz J E, Sunwoo H, Spector D L. Long noncoding RNAs: Func-
tional surprises from the RNA world. Genes Dev, 2009, 23: 
1494–1504 
20 Shimono Y, Zabala M, Cho R W, et al. Downregulation of miR-
NA-200c links breast cancer stem cells with normal stem cells. Cell, 
2009, 138: 592–603 
890 Liu B D, et al.   Sci China Life Sci   October (2013) Vol.56 No.10 
21 Yu F, Yao H, Zhu P, et al. let-7 regulates self-renewal and tumor-
igenicity of breast cancer cells. Cell, 2007, 131: 1109–1123 
22 Yu F, Deng H, Yao H, et al. Mir-30 reduction maintains self-renewal 
and inhibits apoptosis in breast tumor-initiating cells. Oncogene, 
2010, 29: 4194–204 
23 Wong P, Iwasaki M, Somervaille T C P, et al. The miR-17-92 mi-
croRNA polycistron regulates MLL leukemia stem cell potential by 
modulating p21 expression. Cancer Res, 2010, 70: 3833–3842 
24 Li Y, Guessous F, Zhang Y, et al. microRNA-34a inhibits glioblas-
toma growth by targeting multiple oncogenes. Cancer Res, 2009, 69: 
7569–7576 
25 Ji J, Yamashita T, Budhu A, et al. Identification of microRNA-181 
by genome-wide screening as a critical player in EpCAM-positive 
hepatic cancer stem cells. Hepatology, 2009, 50: 472–480 
26 Gregory P A, Bert A G, Paterson E L, et al. The miR-200 family and 
miR-205 regulate epithelial to mesenchymal transition by targeting 
ZEB1 and SIP1. Nat Cell Biol, 2008, 10: 593–601 
27 Park S M, Gaur A B, Lengyel E, et al. The miR-200 family deter-
mines the epithelial phenotype of cancer cells by targeting the 
E-cadherin repressors ZEB1 and ZEB2. Genes Dev, 2008, 22: 
894–907 
28 Burk U, Schubert J, Wellner U, et al. A reciprocal repression between 
ZEB1 and members of the miR-200 family promotes EMT and inva-
sion in cancer cells. EMBO Rep, 2008, 9: 582–589 
29 Ru P, Steele R, Newhall P, et al. miRNA-29b suppresses prostate 
cancer metastasis by regulating epithelial-mesenchymal transition 
signaling. Mol Cancer Ther, 2012, 11: 1166–1173 
30 Zhang J, Zhang H, Liu J, et al. miR-30 inhibits TGF-1-induced epi-
thelial-to-mesenchymal transition in hepatocyte by targeting Snail1. 
Biochem Biophys Res Commun, 2012, 417: 1100–1105 
31 Liu Y N, Yin J J, Abou-Kheir W, et al. miR-1 and miR-200 inhibit 
EMT via Slug-dependent and tumorigenesis via Slug-independent 
mechanisms. Oncogene, 2012, 32: 296–306 
32 Sun L, Yao Y, Liu B, et al. miR-200b and miR-15b regulate chemo-
therapy-induced epithelial-mesenchymal transition in human tongue 
cancer cells by targeting BMI1. Oncogene, 2012, 31: 432–445 
33 Mani S, Guo W, Liao M, et al. The epithelial-mesenchymal transition 
generates cells with properties of stem cells. Cell, 2008, 133: 
704–715 
34 Han M, Liu M, Wang Y, et al. Re-expression of miR-21 contributes 
to migration and invasion by inducing epithelial-mesenchymal transi-
tion consistent with cancer stem cell characteristics in MCF-7 cells. 
Mol Cell Biochem, 2012, 363: 427–436 
35 Han M, Liu M, Wang Y, et al. Antagonism of miR-21 reverses epi-
thelial-mesenchymal transition and cancer stem cell phenotype 
through AKT/ERK1/2 inactivation by targeting PTEN. PLoS ONE, 
2012, 7: e39520 
36 Smith A L, Iwanaga R, Drasin D J, et al. The miR-106b-25 cluster 
targets Smad7, activates TGF- signaling, and induces EMT and tu-
mor initiating cell characteristics downstream of Six1 in human 
breast cancer. Oncogene, 2012, 31: 5162–5171 
37 The ENCODE Project Consortium. An integrated encyclopedia of 
DNA elements in the human genome. Nature 2012, 489: 57–74 
38 Ponting C P, Oliver P L, Reik W. Evolution and functions of long 
noncoding RNAs. Cell, 2009, 136: 629–641 
39 Calin G A, Liu C G, Ferracin M, et al. Ultraconserved regions en-
coding ncRNAs are altered in human leukemias and carcinomas. 
Cancer Cell, 2007, 12: 215–229 
40 Rinn J L, Kertesz M, Wang J K, et al. Functional demarcation of ac-
tive and silent chromatin domains in human HOX loci by noncoding 
RNAs. Cell, 2007, 129: 1311–1323 
41 Gupta R A, Shah N, Wang K C, et al. Long non-coding RNA 
HOTAIR reprograms chromatin state to promote cancer metastasis. 
Nature, 2010, 464: 1071–1076 
42 Ji P, Diederichs S, Wang W, et al. MALAT-1, a novel noncoding 
RNA, and thymosin 4 predict metastasis and survival in early-stage 
non-small cell lung cancer. Oncogene, 2003, 22: 8031–8041 
43 Ying L, Chen Q, Wang Y, et al. Upregulated MALAT-1 contributes 
to bladder cancer cell migration by inducing epithelial-to mesenchy-
mal transition. Mol BioSyst, 2012, 8: 2289–2294 
44 Zhou Y, Zhong Y, Wang Y, et al. Activation of p53 by MEG3 
non-coding RNA. J Biol Chem, 2007, 282: 24731–4742 
45 Zhang X, Gejman R, Mahta A, et al. Maternally expressed gene 3, an 
imprinted noncoding RNA gene, is associated with meningioma 
pathogenesis and progression. Cancer Res, 2010, 70: 2350–2358 
46 Braconi C, Kogure T, Valeri N, et al. microRNA-29 can regulate ex-
pression of the long non-coding RNA gene MEG3 in hepatocellular 
cancer. Oncogene, 2011, 30: 4750–4756 
47 Huarte M, Guttman M, Feldser D, et al. A large intergenic noncoding 
RNA induced by p53 mediates global gene repression in the p53 re-
sponse. Cell, 2010, 142: 409–419 
48 Yang F, Huo X, Yuan S, et al. Repression of the long noncoding 
RNA-LET by histone deacetylase 3 contributes to hypoxia-mediated 
metastasis. Mol Cell, 2013, 49: 1083–1096 
49 Yang L, Lin C, Jin C, et al. lncRNA-dependent mechanisms of an-
drogen-receptor-regulated gene activation programs. Nature, 2013, 
500: 598–602 
 
Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction 
in any medium, provided the original author(s) and source are credited. 
